Europe Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generi

Europe Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)

The Europe pulmonary arterial hypertension market is expected to grow from US$ 1,959.47 million in 2022 to US$ 2,683.07 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2022 to 2028.

Growing Incidence of Pulmonary Arterial Hypertension Drives Europe Pulmonary Arterial Hypertension Market

Pulmonary arterial hypertension (PAH) affects the tiny arteries in the lung, making it thick and narrow and blocking the blood flow through the lungs. As a result, blood pressure in the lungs increases, and the heart faces difficulties in pumping blood through narrowed arteries. Over time, an individual's heart loses the ability to pump blood throughout the body effectively. PAH usually affects women between the ages of 30 and 60. Further, according to an article in European Respiratory Review published in 2019, the incidence of PAH is 7.6 cases per million in Scotland. Idiopathic PAH—in which a family history or an identified risk factor is present—is even rare, recording 2.6 cases per million in Scotland. Thus, the growing incidence of pulmonary arterial hypertension is driving the growth of the Europe pulmonary arterial hypertension market.

Europe Pulmonary Arterial Hypertension Market Overview

The Europe pulmonary arterial hypertension market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the global pulmonary arterial hypertension market. The Europe pulmonary arterial hypertension market is expected to witness significant growth during the forecast period due to a rise in product approvals. Pulmonary hypertension is a rare condition that affects approximately one in 20,000 people in the UK. In 2021, 7,876 individuals in the UK suffered from pulmonary hypertension. In the UK, younger patients suffering from idiopathic pulmonary arterial hypertension (IPAH) have a 5-year survival above 80%. In the UK, patients suffering from PAH and CTEPH (the disease is caused due to a direct consequence of changes in the pulmonary vasculature) are most commonly treated in nine specialist centers across the country. The Pulmonary Hypertension Association UK (PHA-UK) in the UK advocates exclusively for people affected by pulmonary hypertension. Therefore, such initiatives are expected to fuel the pulmonary arterial hypertension drug market in the country during the forecast period.

Europe Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)

Europe Pulmonary Arterial Hypertension Market Segmentation

The Europe pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the Europe pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on type, the Europe pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Europe pulmonary arterial hypertension market.

Based on route of administration, the Europe pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on distribution channel, the Europe pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on country, the Europe pulmonary arterial hypertension market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe pulmonary arterial hypertension market.

Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and United Therapeutics Corp are the leading companies operating in the Europe pulmonary arterial hypertension market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe pulmonary arterial hypertension market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the pulmonary arterial hypertension market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution